{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"0","value":"0"},{"groupId":"OG001","spread":"0","value":"0"},{"groupId":"OG002","spread":"0","value":"0"},{"groupId":"OG003","spread":"0","value":"0"},{"groupId":"OG004","spread":"0","value":"0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"13"},{"groupId":"OG003","value":"6"},{"groupId":"OG004","value":"4"}],"units":"Participants"}],"title":"Course 1, pre-dose"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.115","value":"0.120"},{"groupId":"OG001","spread":"0.526","value":"3.95"},{"groupId":"OG002","spread":"2.98","value":"9.15"},{"groupId":"OG003","spread":"0.984","value":"3.49"},{"groupId":"OG004","spread":"1.95","value":"9.87"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"12"},{"groupId":"OG003","value":"6"},{"groupId":"OG004","value":"3"}],"units":"Participants"}],"title":"Course 1, 1 hour"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0","value":"0.0357"},{"groupId":"OG001","spread":"0.349","value":"2.29"},{"groupId":"OG002","spread":"1.93","value":"6.64"},{"groupId":"OG003","spread":"1.06","value":"2.12"},{"groupId":"OG004","spread":"0.280","value":"7.88"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"12"},{"groupId":"OG003","value":"6"},{"groupId":"OG004","value":"3"}],"units":"Participants"}],"title":"Course 1, 4 hours"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0","value":"0"},{"groupId":"OG001","spread":"0","value":"0"},{"groupId":"OG002","spread":"1.44","value":"0.851"},{"groupId":"OG003","spread":"0","value":"0"},{"groupId":"OG004","spread":"0.0137","value":"0.0136"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"8"},{"groupId":"OG003","value":"6"},{"groupId":"OG004","value":"3"}],"units":"Participants"}],"title":"Course 1, 24 hours"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0","value":"0"},{"groupId":"OG001","spread":"0","value":"0"},{"groupId":"OG002","spread":"0","value":"0"},{"groupId":"OG003","spread":"0","value":"0"},{"groupId":"OG004","spread":"0","value":"0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"13"},{"groupId":"OG003","value":"6"},{"groupId":"OG004","value":"3"}],"units":"Participants"}],"title":"Course 1, 168 hours"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0","value":"0"},{"groupId":"OG001","spread":"2.19","value":"1.26"},{"groupId":"OG002","spread":"0","value":"0"},{"groupId":"OG003","spread":"0","value":"0"},{"groupId":"OG004","spread":"0","value":"0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"11"},{"groupId":"OG003","value":"6"},{"groupId":"OG004","value":"2"}],"units":"Participants"}],"title":"Course 2, pre-dose"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.135","value":"0.148"},{"groupId":"OG001","spread":"0.247","value":"4.10"},{"groupId":"OG002","spread":"2.27","value":"8.47"},{"groupId":"OG003","spread":"1.48","value":"3.23"},{"groupId":"OG004","spread":"2.22","value":"9.63"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"11"},{"groupId":"OG003","value":"6"},{"groupId":"OG004","value":"2"}],"units":"Participants"}],"title":"Course 2, 1 hour"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.0253","value":"0.032"},{"groupId":"OG001","spread":"0.140","value":"2.66"},{"groupId":"OG002","spread":"1.87","value":"6.13"},{"groupId":"OG003","spread":"0.959","value":"1.55"},{"groupId":"OG004","spread":"3.15","value":"7.41"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"11"},{"groupId":"OG003","value":"6"},{"groupId":"OG004","value":"2"}],"units":"Participants"}],"title":"Course 2, 4 hours"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0","value":"0"},{"groupId":"OG001","spread":"0","value":"0"},{"groupId":"OG002","spread":"0.872","value":"0.593"},{"groupId":"OG003","spread":"0","value":"0"},{"groupId":"OG004","spread":"0.0448","value":"0.0317"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"7"},{"groupId":"OG003","value":"6"},{"groupId":"OG004","value":"2"}],"units":"Participants"}],"title":"Course 2, 24 hours"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0","value":"0"},{"groupId":"OG001","spread":"0","value":"0"},{"groupId":"OG002","spread":"0","value":"0"},{"groupId":"OG003","spread":"0","value":"0"},{"groupId":"OG004","spread":"0","value":"0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"10"},{"groupId":"OG003","value":"6"},{"groupId":"OG004","value":"2"}],"units":"Participants"}],"title":"Course 2, 168 hours"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0","value":"0"},{"groupId":"OG001","spread":"0","value":"0"},{"groupId":"OG002","spread":"0","value":"0"},{"groupId":"OG003","spread":"0","value":"0"},{"groupId":"OG004","spread":"0","value":"0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"4"},{"groupId":"OG003","value":"4"},{"groupId":"OG004","value":"2"}],"units":"Participants"}],"title":"Course 3, pre-dose"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0","value":"0.198"},{"groupId":"OG001","spread":"0.721","value":"3.54"},{"groupId":"OG002","spread":"1.98","value":"7.33"},{"groupId":"OG003","spread":"1","value":"1.89"},{"groupId":"OG004","spread":"1.80","value":"9.53"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"4"},{"groupId":"OG003","value":"4"},{"groupId":"OG004","value":"2"}],"units":"Participants"}],"title":"Course 3, 1 hour"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0","value":"0"},{"groupId":"OG001","spread":"0","value":"0"},{"groupId":"OG002","spread":"0","value":"0"},{"groupId":"OG003","spread":"0","value":"0"},{"groupId":"OG004","spread":"0","value":"0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"4"},{"groupId":"OG003","value":"4"},{"groupId":"OG004","value":"1"}],"units":"Participants"}],"title":"Course 4, pre-dose"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0","value":"0.0114"},{"groupId":"OG001","spread":"0","value":"3.98"},{"groupId":"OG002","spread":"3.11","value":"8.82"},{"groupId":"OG003","spread":"1.17","value":"1.26"},{"groupId":"OG004","spread":"0","value":"1.84"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"4"},{"groupId":"OG003","value":"3"},{"groupId":"OG004","value":"1"}],"units":"Participants"}],"title":"Course 4, 1 hour"}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"13"},{"groupId":"OG003","value":"6"},{"groupId":"OG004","value":"5"}],"units":"Participants"}],"description":"Serial blood samples for APX005M pharmacokinetic studies were collected during courses 1 and 2 at pre-dose, at the end of infusion, and at 4, 24 ± 1 (day 2), and 168 ± 4 hours (day 8) from the start of infusion in that course. During courses 3 and 4, samples were obtained pre-dose and end of induction. Serum concentrations of sotigalimab were measured using a validated electrochemiluminescent (ECL) immunoassay (Method ICD 853 v1.00). Mean serum concentrations with standard deviations were calculated using Phoenix® WinNonlin® v.8.4. Concentrations below the limit of quantitation (0.010 μg/mL) were replaced with 0 to calculate means and SDs.","dispersionType":"Standard Deviation","groups":[{"description":"Patients with recurrent or refractory primary malignant CNS tumors received APX005M on day 1 of each 21-day course at 0.1 mg/kg for up to 36 courses or until disease progression, unacceptable toxicity, or death.","id":"OG000","title":"Stratum 1, Dose Level 1"},{"description":"Patients with recurrent or refractory primary malignant CNS tumors received APX005M on day 1 of each 21-day course at 0.3 mg/kg for up to 36 courses or until disease progression, unacceptable toxicity, or death.","id":"OG001","title":"Stratum 1, Dose Level 2"},{"description":"Patients with recurrent or refractory primary malignant CNS tumors received APX005M on day 1 of each 21-day course at 0.6 mg/kg for up to 36 courses or until disease progression, unacceptable toxicity, or death.","id":"OG002","title":"Stratum 1, Dose Level 3"},{"description":"Patients with newly diagnosed diffuse intrinsic pontine glioma (DIPG) received APX005M on day 1 of each 21-day course at 0.3 mg/kg for up to 36 courses or until disease progression, unacceptable toxicity, or death.","id":"OG003","title":"Stratum 2, Dose Level 2"},{"description":"Patients with newly diagnosed diffuse intrinsic pontine glioma (DIPG) received APX005M on day 1 of each 21-day course at 0.6 mg/kg for up to 36 courses or until disease progression, unacceptable toxicity, or death.","id":"OG004","title":"Stratum 2, Dose Level 3"}],"paramType":"MEAN","populationDescription":"Ineligible patients were excluded from all analyses.","reportingStatus":"POSTED","timeFrame":"Up to 12 weeks from start of study drug","title":"Serum Concentration of APX005M","type":"PRIMARY","unitOfMeasure":"μg/mL"}